Wednesday, July 8, 2026

Patent intelligence · US

US 10093790

Three-dimensional cellulose molded body, method for the production thereof and use of the same

granted A61KA61K2800/10A61K2800/654A61K31/167
Status granted
Linked drugs 1
Pipeline programs 5
Years to expiry 12
Applicant portfolio 20
Patent details — US 10093790
Jurisdiction
US
Status
granted
Grant date
Oct 9, 2018
Expiration
Oct 4, 2038
Claims
25
CPC classes
A61K, A61K2800/10, A61K2800/654, A61K31/167
View on Google Patents ↗

Quick answer

US 10093790 (Three-dimensional cellulose molded body, method for the production thereof and use of the same) is held by LENZING AKTIENGESELLSCHAFT. Status: granted. Granted Oct 9, 2018. Expires Oct 4, 2038 (12 years remaining) — relevant for patent-cliff and LOE planning.

Key facts

Grant date
Expiration
Claims
25
CPC classes
A61K, A61K2800/10, A61K2800/654, A61K31/167, A61K8/0279, A61K8/731

More from LENZING AKTIENGESELLSCHAFT

Related pharmaceutical patents in our USPTO index.

  1. US 12414942

    Compositions, methods, and systems for treating presbyopia

    LENZ THERAPEUTICS OPERATIONS, INC. · Expires Sep 11, 2045

    granted
  2. US 12180206

    Aceclidine derivatives, compositions thereof and methods of use thereof

    LENZ THERAPEUTICS OPERATIONS, INC. · Expires Dec 26, 2044

    granted
  3. US 12128036

    Compositions and methods for storage stable ophthalmic drugs

    LENZ THERAPEUTICS OPERATIONS, INC. · Expires Oct 24, 2044

    granted
  4. US 11648247

    Compositions and methods for the treatment of presbyopia

    Lenz Therapeutics, Inc. · Expires May 11, 2043

    granted
  5. US 11344538

    Methods for the treatment of myopia

    Lenz Therapeutics, Inc. · Expires May 26, 2042

    granted
  6. US 11273150

    Compositions and methods for the treatment of presbyopia

    Lenz Therapeutics, Inc. · Expires Mar 10, 2042

    granted
  7. US 11214569

    Prodrugs of quinuclidine ring-containing muscarinic agonists and compositions and methods thereof

    Lenz Therapeutics, Inc. · Expires Dec 30, 2041

    granted
  8. US 11179328

    Compositions and methods for the treatment of presbyopia

    Lenz Therapeutics, Inc. · Expires Nov 18, 2041

    granted

Frequently asked questions

What is US patent 10093790?

US 10093790 (Three-dimensional cellulose molded body, method for the production thereof and use of the same) is held by LENZING AKTIENGESELLSCHAFT. Status: granted. Granted Oct 9, 2018. Expires Oct 4, 2038 (12 years remaining) — relevant for patent-cliff and LOE planning.

Who owns US 10093790?

LENZING AKTIENGESELLSCHAFT is listed as the applicant in USPTO PatentsView records indexed by NovaPharmaNews. We track 20 pharmaceutical patents for this assignee.

When does US 10093790 expire?

Our index shows an expiration date of Oct 4, 2038 (12 years from today). Confirm material dates against USPTO, FDA Orange Book, or qualified counsel before contractual decisions.